Rhode Island Hospital
Providence, Rhode Island, 02912, United States
Location status: Recruiting
NCT Number: NCT05702398
The goal of this clinical trial is to assess the feasibility and safety of oral nicotinamide (NAM; a derivative of vitamin B3 [niacin]) and vitamin A in a high-risk population of kidney transplant recipients with a history of skin cancer to generate preliminary data for future cancer prevention clinical trials.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Early Phase 1
Providence, Rhode Island, 02912, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1,000 μg retinyl palmitate twice a day for 6 months
500 mg NAM twice a day for 6 months
Other names: Niacin (Vitamin B3)
Identical placebo pills twice a day
Time frame: 6 months
Contact information is provided by the study sponsor or research team.
Rhode Island Hospital
Other
Pilot Trial of Supplemental Vitamin A and Nicotinamide and Levels of Blood Vitamin A and Nicotinamide
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07042243
Behavior, Behavior, Animal
Gainesville, Florida, United States
View Trial DetailsNCT04122456
Neoplasms, Neoplasms by Site
Fairborn, Ohio, United States
View Trial DetailsNCT06615635
Alpha Radiation, Brachytherapy
Gilbert, Arizona, United States
View Trial DetailsNCT07247123
Benign Skin Growth, Neoplasms
Singapore
View Trial Details